Bruce Psaty is a general internist and cardiovascular disease epidemiologist with interests and expertise in pharmaco-epidemiology, pharmacogenetics, and drug safety. Also a professor of medicine, epidemiology, and health services at the University of Washington (UW), he co-directs the UW’s Cardiovascular Health Research Unit.
Dr. Psaty’s work includes population-based case-control studies of myocardial infarction, stroke, atrial fibrillation, and venous thromboembolism conducted at Group Health Cooperative. His primary research interests include risk factors such as high blood pressure, dyslipidemia, and diabetes and the drugs used to treat these conditions; new or emerging risk factors for heart disease and stroke; genetics, genomics, and pharmacogenetics; and genetic risk factors for a variety of conditions.
His several current NIH-funded projects focus on interactions between medications and genes; they represent efforts to translate findings from the Human Genome Project into clinical practice and, thus, improve the safety and efficacy of commonly used medications. He is a founding member of the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium (CHARGE), which conducts genome-wide association studies in collaborating cohorts, including the Cardiovascular Health Study and the Multi-Ethnic Study of Atherosclerosis, funded by the National Heart, Lung, and Blood Institute. He also teaches and mentors students, fellows, and junior faculty in medicine and epidemiology.
A national leader in encouraging better postmarket surveillance of approved medications, Dr. Psaty is a member of the U.S. Food and Drug Administration (FDA)’s Science Board, a committee that advises the commisioner and chief scientist. He previously served on two Institute of Medicine (IOM) panels charged with reviewing the FDA, most recently the ethical and scientific issues in studying the safety of approved drugs. Dr. Psaty is also a member of the National Heart, Lung, and Blood Institute’s Advisory Council. In 2013, he was elected to the IOM and designated a distinguished scientist by the American Heart Association.
Dr. Psaty maintains a small but long-standing primary care practice in the Adult Medicine Clinic at Harborview Medical Center.
Smith NL, Harrington LB, Blondon M, Wiggins KL, Floyd JS, Sitlani CM, McKnight B, Larson EB, Rosendaal FR, Heckbert SR, Psaty BM. The association of statin therapy with the risk of recurrent venous thrombosis. J Thrombos Haemost. 2016 Apr 8. doi: 10.1111/jth.13334. [Epub ahead of print]. PubMed
Floyd JS, Brody JA, Tiniakou E, Psaty BM, Mammen A. Absence of anti-HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy. Muscle Nerve. 2016 Mar 31. doi: 10.1002/mus.25127. [Epub ahead of print]. PubMed
Sharfstein JM, Psaty BM. Evaluation of the cardiovascular risk of naltrexone-bupropion: a study interrupted. JAMA. 2016;315(10):984-6. doi: 10.1001/jama.2016.1461. PubMed
Willems SM, Cornes BK, Brody JA, Morrison AC, Lipovich L, Dauriz M, Chen Y, Liu CT, Rybin DV, Gibbs RA, Muzny D, Pankow JS, Psaty BM, Boerwinkle E, Rotter JI, Siscovick DS, Vasan RS, Kaplan RC, Isaacs A, Dupuis J, van Duijn CM, Meigs JB. Association of the IGF1 gene with fasting insulin levels. Eur J Hum Genet. 2016 Feb 10. doi: 10.1038/ejhg.2016.4 [Epub ahead of print]. PubMed
Dr. Sascha Dublin describes a Group Health-UW finding that benzodiazepines probably don’t cause dementia. But she cautions that they’re still bad for you.
Read it in Healthy Findings.
New York Times, Feb 13, 2012